111 related articles for article (PubMed ID: 11102954)
1. Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.
Grande M; Carlström K; Lundh Rozell B; Eneroth P; Stege R; Pousette A
Prostate; 2000 Dec; 45(4):299-303. PubMed ID: 11102954
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
Grande M; Carlström K; Rozell BL; Stege R; Pousette A
Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
4. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy.
Stege RH; Tribukait B; Carlström KA; Grande M; Pousette AH
Prostate; 1999 Feb; 38(3):183-8. PubMed ID: 10068342
[TBL] [Abstract][Full Text] [Related]
5. Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma.
Grande M; Carlström K; Lundh-Rozell B; Stege R; Pousette A
Scand J Urol Nephrol; 2005; 39(5):393-8. PubMed ID: 16257841
[TBL] [Abstract][Full Text] [Related]
6. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Nilsson B; Nordström L
Prostate; 1985; 6(3):285-91. PubMed ID: 3991370
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
9. Tissue PSA is the best predicting variable for the outcome of endocrine treatment of prostatic carcinoma.
Pousette A; Grande M; Carlström K; Stege R
Scand J Clin Lab Invest Suppl; 1999; 229():27-32. PubMed ID: 10097287
[TBL] [Abstract][Full Text] [Related]
10. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K
Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.
Kuban DA; el-Mahdi AM; Schellhammer PF
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):307-16. PubMed ID: 7538499
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
13. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
14. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
15. The 1989 patterns of care study for prostate cancer: five-year outcomes.
Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
17. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
18. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
Zagars GK; Kavadi VS; Pollack A; von Eschenbach AC; Sands ME
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):21-32. PubMed ID: 7536722
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988-1992.
Schneider SB; Schweitzer VG; Parker RG; Bycott PW
Am J Clin Oncol; 1996 Feb; 19(1):65-72. PubMed ID: 8554039
[TBL] [Abstract][Full Text] [Related]
20. Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
Kil PJ; Goldschmidt HM; Wieggers BJ; Kariakine OB; Studer UE; Whelan P; Hetherington J; de Reijke TM; Hoekstra JW; Collette L
Eur Urol; 2003 Jan; 43(1):31-8. PubMed ID: 12507541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
